N-[2-(N-tert-butoxycarbonylamino)phenyl]-4-[N-[3-[(pyridin-3-yl)methylamino]cyclobuten-1,2-dion-4-yl]aminomethyl]benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(N-tert-butoxycarbonylamino)phenyl]-4-[N-[3-[(pyridin-3-yl)methylamino]cyclobuten-1,2-dion-4-yl]aminomethyl]benzamide
• 英文别名: tert-butyl N-[2-[[4-[[[2-[methyl(pyridin-3-yl)amino]-3,4-dioxocyclobuten-1-yl]amino]methyl]benzoyl]amino]phenyl]carbamate
• 化学式: C₂₉H₂₉N₅O₅
• 分子量: 527.58
• InChiKey: UAZYLCJMDVOOMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-氨甲基吡啶 、 方酸二正丁酯 以 四氢呋喃 、 水 为溶剂， 以78%的产率得到N-[2-(N-tert-butoxycarbonylamino)phenyl]-4-[N-[3-[(pyridin-3-yl)methylamino]cyclobuten-1,2-dion-4-yl]aminomethyl]benzamide
  参考文献：
  名称：

  Cell differentiation inducer

  摘要：

  本发明所代表的新型苯甲酰胺衍生物（式（1）所代表）和新型苯胺酰衍生物（式（13）所代表）具有诱导分化作用，因此可作为治疗或改善恶性肿瘤、自身免疫疾病、皮肤病和寄生病的药物或改善剂。特别是，它们作为抗癌药物非常有效，特别适用于血液恶性肿瘤和实体肿瘤。

  公开号：

  US06174905B1

文献信息

• New pharmaceutical combination
  申请人：Schuppan Detlev

  公开号：US20050054647A1

  公开（公告）日：2005-03-10

  Pharmaceutical combinations comprising at least one compound of general formula I-A or I-AA, and at lest one compound of general formula II) or Iia), or pharmaceutical combinations comprising at least one compound of general formula I-A or I-AA, and at least one compound of general formula II) or Iia), and an anti-hormone, and their use for the treatment of different diseases resulting by persistent angiogenesis are described.

  本文描述了包含至少一个I-A或I-AA通用式化合物和至少一个II）或Iia）通用式化合物的制药组合物，或包含至少一个I-A或I-AA通用式化合物和至少一个II）或Iia）通用式化合物以及抗激素的制药组合物，并用于治疗由持续血管生成引起的不同疾病。
• CELL DIFFERENTIATION INDUCER
  申请人：Suzuki Tsuneji

  公开号：US20100256201A1

  公开（公告）日：2010-10-07

  The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

  本发明的公式（1）所代表的新型苯甲酰胺衍生物和公式（13）所代表的新型苯酰胺衍生物具有诱导分化的效果，因此可作为治疗或改善恶性肿瘤、自身免疫性疾病、皮肤病和寄生虫病的治疗药物或改善剂。特别是，它们对血液恶性肿瘤和实体癌具有高度的抗癌作用。
• Benzamide derivatives, useful as cell differentiation inducers
  申请人：MITSUI CHEMICALS, INC.

  公开号：EP0847992A1

  公开（公告）日：1998-06-17

  The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

  本发明的式(1)代表的新型苯甲酰胺衍生物和式(13)代表的新型苯胺衍生物具有分化诱导作用，因此可用于治疗或改善恶性肿瘤、自身免疫性疾病、皮肤病和寄生虫病。特别是，它们作为抗癌药物，尤其是对血液系统恶性肿瘤和实体癌非常有效。
• Benzamide derivatives useful as cell differentiation inducers
  申请人：Schering AG

  公开号：EP1437346A1

  公开（公告）日：2004-07-14

  The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

  本发明的式(1)代表的新型苯甲酰胺衍生物和式(13)代表的新型苯胺衍生物具有分化诱导作用，因此可用于治疗或改善恶性肿瘤、自身免疫性疾病、皮肤病和寄生虫病。特别是，它们作为抗癌药物，尤其是对血液系统恶性肿瘤和实体癌非常有效。
• Pharmaceutical combinations comprising cis-retine acid
  申请人：Schering Aktiengesellschaft

  公开号：EP1738752A1

  公开（公告）日：2007-01-03

  Pharmaceutical combinations comprising at least 9cis-retine acid (CRA), 13cis-retine acid, or a derivative thereof, at least one compound of general formula II), and an anti-hormone, and their use for the treatment of different diseases resulting by persistent angiogenesis are described.

  本文描述了由至少 9cis-retine acid (CRA)、13cis-retine acid 或其衍生物、至少一种通式 II) 的化合物和一种抗激素组成的药物组合，以及它们在治疗由持续血管生成导致的不同疾病中的用途。